Finding new biomarkers for biliary tract cancer and gallbladder cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify new diagnostic, prognostic, and predictive biomarkers for biliary tract cancer (BTC), which includes cholangiocarcinoma and gallbladder cancer. Given the poor prognosis associated with BTC, the study will collect biological materials such as blood samples and tissue from patients undergoing standard or protocolized treatment. The goal is to enhance early diagnosis, improve prognostication, and predict treatment efficacy through the analysis of these biomarkers. Patients will be monitored throughout their treatment journey to assess the effectiveness of the identified biomarkers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histological or cytological diagnosis of BTC
* Patients referred for treatment of BTC
* Signed informed consent

Exclusion Criteria:

* None

Where it's running

• Herlev & Gentofte Hospital
  Herlev, Copenhagen, Denmark Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing MDX2001 for advanced solid tumors

  This study is testing a new drug called MDX2001 to see if it can safely help people with advanced solid tumors like breast or colon cancer.

  Recruiting at 6 sites Phase 1/2 ModeX Therapeutics, An OPKO Health Company · Denver, Colorado and 5 other locations · NCT06239194

• Dual-target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer

  This trial tests a ready-to-use CAR-NK cell therapy that targets HER2 and CEACAM5 in adults with unresectable or metastatic biliary tract cancers after standard therapy to see if it can help control the disease.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07641036

• Anti-blood-vessel therapy after immunotherapy for advanced bile duct or gallbladder cancer.

  This study will test whether giving the anti-angiogenic drug anlotinib after first-line immunotherapy helps people with advanced bile duct or gallbladder cancer live longer without their disease getting worse.

  Recruiting Phase 2 First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT07025174

• Evaluating biomarkers in advanced biliary tract cancer treatment with lenvatinib and pembrolizumab

  This study is testing if a combination of two drugs, lenvatinib and pembrolizumab, can help people with advanced biliary tract cancer and is looking for clues in their genetic data to see how well the treatment works.

  Recruiting CHA University · Seongnam-si, Gyeonggi-do · NCT06648057

• Combining chemotherapy, immunotherapy, radiation, and heat treatment for advanced biliary tract cancer

  This study is testing a new combination of chemotherapy, immunotherapy, radiation, and heat treatment to see if it can help people with advanced biliary tract cancer who can’t have surgery.

  Recruiting at 2 sites Phase 1 University of Maryland, Baltimore · Baltimore, Maryland and 1 other locations · NCT06546969

• Combination chemotherapy for patients with resectable biliary tract cancers

  This study is testing a new combination of chemotherapy drugs before surgery to see if it helps people with certain types of biliary tract cancers live longer without their cancer coming back.

  Recruiting at 2 sites Phase 2/3 Gruppo Oncologico del Nord-Ovest · Ancona and 18 other locations · NCT06037980

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.